Meet with...Merck | Application Deadline September 3, 2010

In this session, Licensing Directors from Merck & Co., Inc. will talk to potential licensees to first explain what they are looking for in a company. After the presentation, attendees will have lunch with the Merck team.

Finally, each pre-approved attendee* will be granted a private meeting with Dr. James M. Schaeffer - the Executive Director of Licensing & External Research for Merck Research Laboratories at Merck & Co., Inc. - or Dr. Yael Weiss - the Director of Licensing & External Research for Merck Research Laboratories at Merck & Co., Inc.

Merck & Co., Inc. is interested in:
*Novel patented compounds
*Targets with proof of concept
*Molecules with a defined mechanism of action or testable hypothesis'
*Technologies with patent protection that provide a competitive advantage

Late-stage clinical compounds with proven therapeutic value (phase IIb or beyond) are of interest in any therapeutic area. Merck & Co., Inc., is most interested in novel compounds that have large market potential for unmet medical needs. An attractive compound would have selectivity, potency, a demonstrated mechanism of action, preliminary toxicology data, oral availability, and a good half-life for once-daily administration. We also look for strong intellectual property protection on the target and the molecule.

*Registrations to one-on-one meetings are subject to approval of application. To apply, please send your Executive Summary by September 3, 2010 to [email protected]. The Review Board, composed of the BioCenter management team, sponsors, partners and mentors, will then meet to consider your application. You will be notified on September 10, 2010 if your application is accepted or rejected. Registration must be completed upon approval to secure your meeting slot.

Official Website: http://www.sjbiocenter.com/event/ev_2010Q3-MeetWithMerck.html